130 related articles for article (PubMed ID: 37776631)
1. Letter re: Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
Aix Ponce S; Cousin S; Dubos P; Belcaid L; Bayle A; Italiano A
Eur J Cancer; 2023 Nov; 193():113309. PubMed ID: 37776631
[No Abstract] [Full Text] [Related]
2. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer.
Kim CG; Hong M; Jeung HC; Lee G; Chung HC; Rha SY; Kim HS; Lee CK; Lee JH; Han Y; Kim JH; Lee SY; Kim H; Shin SJ; Baek SE; Jung M
Eur J Cancer; 2022 Sep; 172():387-399. PubMed ID: 35839733
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
[TBL] [Abstract][Full Text] [Related]
4. PD-1
Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
[TBL] [Abstract][Full Text] [Related]
5. Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer.
Chen S; Han L; Guo S; Tan Z; Dai G
Hum Vaccin Immunother; 2023 Aug; 19(2):2252692. PubMed ID: 37675466
[TBL] [Abstract][Full Text] [Related]
6. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
[TBL] [Abstract][Full Text] [Related]
7. Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs.
Kim KH; Hur JY; Koh J; Cho J; Ku BM; Koh JY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ; Shin EC
Immune Netw; 2020 Dec; 20(6):e48. PubMed ID: 33425433
[TBL] [Abstract][Full Text] [Related]
8. Treg-Dominant Tumor Microenvironment Is Responsible for Hyperprogressive Disease after PD-1 Blockade Therapy.
Wakiyama H; Kato T; Furusawa A; Okada R; Inagaki F; Furumoto H; Fukushima H; Okuyama S; Choyke PL; Kobayashi H
Cancer Immunol Res; 2022 Nov; 10(11):1386-1397. PubMed ID: 36169564
[TBL] [Abstract][Full Text] [Related]
9. Case Report: Tumor Microenvironment Characteristics in a Patient With HER2 Mutant Lung Squamous Cell Carcinoma Harboring High PD-L1 Expression Who Presented Hyperprogressive Disease.
Xia L; Yu Y; Lan F; Yan J; Li J; Li W; Xia Y
Front Oncol; 2021; 11():760703. PubMed ID: 35004282
[TBL] [Abstract][Full Text] [Related]
10. Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer.
Li Y; Chen T; Nie TY; Han J; He Y; Tang X; Zhang L
Front Immunol; 2023; 14():1200875. PubMed ID: 37283759
[TBL] [Abstract][Full Text] [Related]
11. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
[TBL] [Abstract][Full Text] [Related]
12. Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer.
Wang X; Guo Z; Wu X; Chen D; Wang F; Yang L; Luo M; Wu S; Yang C; Huang L; Fu L
Immunotargets Ther; 2023; 12():1-16. PubMed ID: 36632330
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
[TBL] [Abstract][Full Text] [Related]
14. Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer.
Aoki M; Shoji H; Nagashima K; Imazeki H; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Higuchi K; Boku N
ESMO Open; 2019; 4(3):e000488. PubMed ID: 31231567
[TBL] [Abstract][Full Text] [Related]
15. Hyperprogressive Disease in the Irradiation Field after a Single Dose of Nivolumab for Gastric Cancer: A Case Report.
Ogata T; Satake H; Ogata M; Hatachi Y; Yasui H
Case Rep Oncol; 2018; 11(1):143-150. PubMed ID: 29681813
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma.
Sun D; Liu D; Liu Q; Hou H
Cancer Biol Ther; 2020 Dec; 21(12):1097-1104. PubMed ID: 33151119
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study.
Zhang X; Zhang C; Hou H; Zhang Y; Jiang P; Zhou H; Wang L; Zhou N; Zhang X
Transl Oncol; 2023 May; 31():101657. PubMed ID: 36934638
[TBL] [Abstract][Full Text] [Related]
18. Who will suffer from hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
Tachihara M; Nishimura Y
J Thorac Dis; 2019 May; 11(Suppl 9):S1289-S1291. PubMed ID: 31245112
[No Abstract] [Full Text] [Related]
19. Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
Maesaka K; Sakamori R; Yamada R; Tahata Y; Imai Y; Ohkawa K; Miyazaki M; Mita E; Ito T; Hagiwara H; Yakushijin T; Kodama T; Hikita H; Tatsumi T; Takehara T
Hepatol Res; 2022 Mar; 52(3):298-307. PubMed ID: 34918428
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Neoadjuvant PD-1 Blockade Plus Concurrent Chemoradiotherapy in Unresectable Locally Advanced Gastric Cancer Patients.
Wei J; Lu X; Liu Q; Li L; Liu S; Liu F; Fu Y; Fan X; Yang Y; Qi C; Yu Y; Guan W; Liu B
Front Oncol; 2020; 10():554040. PubMed ID: 33634011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
